Top

Published in:

Open Access 01-12-2013 | Erratum

Erratum to: Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy

Authors: Joris van Ark, Hans-Peter Hammes, Marcory CRF van Dijk, Chris PH Lexis, Iwan CC van der Horst, Clark J Zeebregts, Marc G Vervloet, Bruce HR Wolffenbuttel, Harry van Goor, Jan-Luuk Hillebrands

Published in: Cardiovascular Diabetology | Issue 1/2013

Excerpt

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all coauthors. The full list of authors has now been added and the Authors’ contributions and Competing interests section modified accordingly. …

van Ark J, Hammes HP, van Dijk MC, Vervloet MG, Wolffenbuttel BH, van Goor H, Hillebrands JL: Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy. Cardiovasc Diabetol. 2013, 12: 116-10.1186/1475-2840-12-116. 14 August 2013PubMedCentralCrossRefPubMed

Title: Erratum to: Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy
Authors: Joris van Ark
Hans-Peter Hammes
Marcory CRF van Dijk
Chris PH Lexis
Iwan CC van der Horst
Clark J Zeebregts
Marc G Vervloet
Bruce HR Wolffenbuttel
Harry van Goor
Jan-Luuk Hillebrands
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-12-120

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2013

Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study

Preserved endothelium-dependent dilatation of the coronary microvasculature at the early phase of diabetes mellitus despite the increased oxidative stress and depressed cardiac mechanical function ex vivo

24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study

Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates

Coronary aspirate TNFα reflects saphenous vein bypass graft restenosis risk in diabetic patients

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials